Diffuse Lung Disease |

Clinical Significance of Proteoglycan Syndecan-4 in Sarcoidosis FREE TO VIEW

Yoshinori Tanino, MD; Xintao Wang, MD; Takefumi Nikaido, MD; Kenichi Misa, MD; Yuki Sato, MD; Ryuichi Togawa, MD; Yasuhito Suzuki, MD; Manabu Uematsu, MD; Atsuro Fukuhara, MD; Suguru Sato, MD; Junpei Saito, MD; Mitsuru Munakata, MD
Author and Funding Information

Fukushima Medical University, Fukushima, Japan

Chest. 2015;148(4_MeetingAbstracts):397A. doi:10.1378/chest.2280558
Text Size: A A A
Published online


SESSION TITLE: Diffuse Lung Disease Posters

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 28, 2015 at 01:30 PM - 02:30 PM

PURPOSE: Syndecan-4 is a transmembrane heparan sulfate proteoglycan which is expressed in a variety of cells such as B lineage lymphocyte and neutrophils. Heparan sulfate glycosaminoglycan side chains of syndecan-4 binds to several proteins such as cytokines suggesting to have various biological activities. Syndecan-4 exists as a soluble form by shedding as well as on cell surfaces. We have previously demonstrated that serum syndecan-4 is increased in patients with acute pneumonia and is upregulated in bronchial epithelial cells and alveolar macrophages in patients with idiopathic pulmonary fibrosis. Our goal was to determine the role of syndecan-4 in sarcoidosis.

METHODS: At first, the levels of syndecan-4 in serum and BAL fluid of patients with sarcoidosis were measured and compared with patients with other pulmonary diseases and healthy subjects. Next, relationship of syndecan-4 in serum and BAL fluid with clinical parameters was analyzed in patients with sarcoidosis. At last, immunohistochemical analysis for syndecan-4 was performed in lung tissues from patients with sarcoidosis.

RESULTS: The serum levels of syndecan-4 were significantly higher in patients with sarcoidosis than in patients with other pulmonary diseases and healthy subjects. In addition, the serum levels of syndecan-4 were significantly correlated with ACE, not with soluble IL-2 receptor in patients with sarcoidosis. In BAL fluid, the levels of syndecan-4 were higher in patients with both sarcoidosis and other pulmonary diseases compared to healthy subjects, and had positive correlation with the percent neutrophils and lymphocytes in BAL fluid. Immunohistochemical analysis showed syndecan-4 was strongly expressed in mononuclear cells and epithelioid cells surrounding the granulomas in lung tissues.

CONCLUSIONS: These findings suggest that syndecan-4 involved in the pathogenesis of sarcoidosis, and the serum syndecan-4 may be clinically useful as a biomarker in patients with sarcoidosis.

CLINICAL IMPLICATIONS: Serum syndecan-4 is a possible biomarker in patients with sarcoidosis.

DISCLOSURE: The following authors have nothing to disclose: Yoshinori Tanino, Xintao Wang, Takefumi Nikaido, Kenichi Misa, Yuki Sato, Ryuichi Togawa, Yasuhito Suzuki, Manabu Uematsu, Atsuro Fukuhara, Suguru Sato, Junpei Saito, Mitsuru Munakata

No Product/Research Disclosure Information




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543